Cargando…
Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes
Achieving hypertension (HTN) control and mitigating the adverse health effects associated with HTN continues to be a global challenge. Some individuals respond poorly to current HTN therapies, and mechanisms for response variation remain poorly understood. We used a nontargeted metabolomics approach...
Autores principales: | Rotroff, DM, Shahin, MH, Gurley, SB, Zhu, H, Motsinger‐Reif, A, Meisner, M, Beitelshees, AL, Fiehn, O, Johnson, JA, Elbadawi‐Sidhu, M, Frye, RF, Gong, Y, Weng, L, Cooper‐DeHoff, RM, Kaddurah‐Daouk, R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716583/ https://www.ncbi.nlm.nih.gov/pubmed/26783503 http://dx.doi.org/10.1002/psp4.12017 |
Ejemplares similares
-
Pharmacometabolomics Reveals Racial Differences in Response to Atenolol Treatment
por: Wikoff, William R., et al.
Publicado: (2013) -
Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans
por: Rotroff, Daniel M., et al.
Publicado: (2016) -
Pharmacometabolomics Informs About Pharmacokinetic Profile of Methylphenidate
por: Kaddurah‐Daouk, Rima, et al.
Publicado: (2018) -
Purine Pathway Implicated in Mechanism of Resistance to Aspirin Therapy: Pharmacometabolomics-Informed-Pharmacogenomics
por: Yerges-Armstrong, Laura M., et al.
Publicado: (2013) -
Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine
por: Beger, Richard D., et al.
Publicado: (2020)